Publications by authors named "Sudipa Roy"

Claim this Profile
S
Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy.
Arpan Satsangi, Sudipa S Roy, Rajiv K Satsangi, Anthony W Tolcher, Ratna K Vadlamudi

Biomaterials· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Samaya R Krishnan, Binoj C Nair, Gangadhara R Sareddy, Sudipa Saha Roy, Mohan Natarajan

Breast Cancer Res Treat· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TATN-1 mutations reveal a novel role for tyrosine as a metabolic signal that influences developmental decisions and longevity in Caenorhabditis elegans.
Annabel A Ferguson, Sudipa Roy, Kaitlyn N Kormanik, Yongsoon Kim, Kathleen J Dumas

PLoS Genet· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Vijay K Gonugunta, Gangadhara R Sareddy, Samaya Rajeshwari Krishnan, Valerie Cortez, Sudipa Saha Roy

Mol Cancer Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.
Sudipa S Roy, Nameer B Kirma, Bindu Santhamma, Rajeshwar R Tekmal, Joseph K Agyin

Cancer Chemother Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells.
Arpan Satsangi, Sudipa S Roy, Rajiv K Satsangi, Ratna K Vadlamudi, Joo L Ong

Mol Pharm· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
Joseph K Agyin, Bindu Santhamma, Sudipa S Roy

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of PELP1 in ER-negative breast cancer metastasis.
Sudipa Roy, Dimple Chakravarty, Valerie Cortez, Keya De Mukhopadhyay, Abhik Bandyopadhyay

Mol Cancer Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
Dimple Chakravarty, Sudipa Saha Roy, Challa Ram Babu, Rajasekhar Dandamudi, Tyler J Curiel

Clin Cancer Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BU-32: a novel proteasome inhibitor for breast cancer.
Joseph K Agyin, Bindu Santhamma, Hareesh B Nair, Sudipa S Roy, Rajeshwar R Tekmal

Breast Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of sulfhydryl groups in band 3 in the inhibition of phosphate transport across erythrocyte membrane in visceral leishmaniasis.
Sudipa Saha Roy, Gargi Sen, Tuli Biswas

Arch Biochem Biophys· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis